---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-25-000102"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:12:06.821223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027

## Summary
- Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.
- Net loss $26.5M vs $29.8M YoY; R&D expense fell to $22.0M from $27.2M.
- First patient dosed in November 2025 in open-label extension of Phase 2 ALTITUDE-AD trial of sabirnetug.
- Expect non-clinical data for EBD candidate in early 2026; Phase 2 topline results in late 2026.
- Added biopharma veteran George Golumbeski as Chairman, board expanded to 8 members.

## SEC filing metadata
- accession: 0001576885-25-000102
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/0001576885-25-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-25-000102
- JSON: https://secwatch.observer/filing/0001576885-25-000102.json
- Plain text: https://secwatch.observer/filing/0001576885-25-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.